Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304162 | 1.00 | AR (0.57) | ARALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL2765554 | 0.88 | AR (0.72) | ARALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL27650930 | 0.88 | AR (0.72) | ARALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL14036039 | 0.87 | AR (0.55) | ARALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL2769356 | 0.87 | AR (0.55) | ARALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL16471047 | 0.87 | AR (0.55) | ARALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL27630726 | 0.86 | AR (0.69) | ARALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL27630713 | 0.84 | AR (0.57) | ARPGRCYP3A4 | |
| SCHEMBL13244698 | 0.84 | AR (0.80) | ARPGRCYP3A4 | |
| SCHEMBL8409323 | 0.84 | AR (0.80) | ARPGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011785-A1 | LOCALLY ACTIVE \"SOFT\" ANTIANDROGENS | YALE UNIVERSITY (US) | 2014-01-09 | — | — | US | disclosed |
| US-7205437-B2 | Selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011785-A1 | LOCALLY ACTIVE \"SOFT\" ANTIANDROGENS | SHBG, CYP17A1, CYP19A1 | AR 4/4885ALDH1A1 409/4885MEN1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.